OTCMKTS:HYPMY Hypermarcas 3/20/2025 Earnings Report $3.71 -0.52 (-12.29%) As of 10/8/2025 03:54 PM Eastern ProfileEarnings HistoryForecast Hypermarcas EPS ResultsActual EPS$0.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AHypermarcas Revenue ResultsActual Revenue$258.56 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHypermarcas Announcement DetailsQuarterDate3/20/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsHypermarcas' next earnings date is estimated for Wednesday, October 29, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Hypermarcas Earnings HeadlinesBrazil's Hypera announces new majority stakeholder groupJuly 7, 2025 | reuters.comHypera S.A. (HYPMY) Stock Price, Quote, News & Analysis - Seeking AlphaJune 29, 2025 | seekingalpha.comArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves. | Banyan Hill Publishing (Ad)Hypera S.A. credit rating downgraded due to increased leverageApril 9, 2025 | investing.comHypera SA (HYPMY) Q4 2024 Earnings Call Highlights: Navigating Growth and ChallengesMarch 24, 2025 | finance.yahoo.comHypera S.A. Reports 2024 Financial PerformanceMarch 21, 2025 | tipranks.comSee More Hypermarcas Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Hypermarcas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hypermarcas and other key companies, straight to your email. Email Address About HypermarcasHypermarcas (OTCMKTS:HYPMY) S.A. is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors. Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products. Its pharmaceutical lineup includes analgesics, anti-inflammatories, vitamins and dermatological preparations, while its consumer goods segment encompasses shampoos, soaps, lotions and oral hygiene items under multiple local brands. Primarily focused on the domestic Brazilian market, Hypermarcas has also extended its reach into other Latin American countries via export partnerships and regional distributors. Over the years, the company has grown through acquisitions of smaller domestic drugmakers and consolidation of well-known local brands. Detailed executive leadership information is not widely available in public sources.View Hypermarcas ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)BlackRock (10/14/2025)ASML (10/15/2025)Kinder Morgan (10/15/2025)Bank of America (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
